07/15/2026

Recent Oncology Related FDA Approvals and Expanded Indications

 

FDA approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance

FDA approves Gilead's Trodelvy® in combination with Merck's KEYTRUDA® or KEYTRUDA QLEX™ for treatment of Advanced Triple-Negative Breast Cancer in adults

FDA approves AstraZeneca's Truqap combination as targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

FDA approves AstraZeneca's Datroway TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates

 

More Info